
    
      Epitinib could cross BBB and show its efficacy in brain metastasis tumors. Patients with
      histologically confirmed glioblastoma; standard treatment failed or no standard treatment as
      well as EGFR gene amplication are eligible. Patients will receive epitinib 120mg or 160mg
      epitinib daily. Epitinib is orally administered qd until patients reach intolerance or
      progression of disease. Tumor assessment takes place every 4 weeks. Simon two stage design
      was used, estimated making sample size of 35 cases.
    
  